Start typing to see results...

Home
>
Stock Market
>
>
Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd share price and stock overview

Q: What is the NSE symbol and BSE code for Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd trades on NSE under the symbol GLENMARK and on BSE under code 532296. The ISIN is INE935A01035 and the face value is Rs 1.

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) operates in the Pharmaceuticals - Indian - Bulk Drugs & Formln sector. The stock has an ISIN of INE935A01035 and a face value of Rs 1. As of 11 July 2026, it trades at Rs (2,282.90) with a market capitalisation of Rs 64405.28 crore. Figures are live and subject to change.

Glenmark Pharmaceuticals Ltd

Pharmaceuticals - Indian - Bulk Drugs & Formln

NSE BSE

2,282.90 15.70 (0.69%) upARrowC

As on: 11-Jul-2026 , 08:12 PM

Market Cap(₹Cr) 64405.28

Book Value(₹Cr) 855.7849313

BSE Code : 532296 NSE Symbol : GLENMARK EPS(TTM) : 56.7 ISIN Demat : INE935A01035 P/E(TTM) : 40.25 Face Value(₹) : 1 Div & Yield % : 0.11

Today Market

Stock Performance

Today Market

Today's High

77,642.23

Todday's Low

77,320.56

Open at

77,395.63

Previous Close

76,741.82

Volumes

Avg Price

827.57

Historical Performance

News

06 Jul 26

Glenmark USA launches Olanzapine for Injection

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial.

06 Jul 26

Glenmark Pharmaceuticals Ltd stays supported

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2260.

06 Jul 26

Glenmark Pharma gains as US arm launches generic Olanzapine injection

The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, marketed by Cheplapharm Registration GmbH under NDA 021253.

02 Jul 26

Glenmark advances multi-country Phase 3 clinical trial for Trastuzumab rezetecan

Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC).

Historical Prices

Share Price Chart

Historical Share Price

Date	Open Price (₹)	High Price(₹)	Low Price(₹)	Close Price(₹)	Total Volume	No of Trades	Net Turnover(₹)	NIFTY
10-07-26	2283.90	2304.10	2247.00	2282.90	602305	31345	1375354817.50	24206.90
09-07-26	2227.90	2293.80	2227.10	2267.20	427091	38505	971156954.70	23962.80
08-07-26	2267.00	2283.60	2212.60	2223.70	337287	23175	757232104.00	23882.05
07-07-26	2278.00	2293.90	2243.00	2264.90	770737	47039	1751619333.50	24398.70
06-07-26	2220.00	2275.00	2216.10	2270.90	600450	34654	1354205661.60	24430.35
03-07-26	2185.20	2244.50	2185.20	2211.00	632010	34053	1402068681.20	24270.85
02-07-26	2174.90	2214.90	2142.80	2196.00	526651	33852	1154922198.00	24175.70
01-07-26	2196.40	2221.20	2153.10	2161.90	455357	26168	988844533.60	24005.85
30-06-26	2186.70	2220.00	2184.50	2204.30	830485	44834	1831133019.60	23865.75
29-06-26	2169.90	2216.30	2158.10	2186.60	1414518	95057	3101462981.00	23946.25

12 3 ...

Fundamentals

Company Valuation

Market Cap (₹cr)

64405.28

PE Ratio

40.25

PB Ratio

2.67

Dividend Yield

0.11

ROE

6.78

ROCE

8.94

Book Value (₹)

855.7849313

Face Value (₹)

Share Holding Pattern

Category of Shareholder	No of Shares	% Share Holdings	Demat Shares	Share Holders

Promoter & Group

Foreign

Foreign (Promoter & Group) - Bodies Corporate	0	0.00	0	0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign)	0	0.00	0	0
Foreign Promoter(Institutional)	0	0.00	0	0
Promoter Others	0	0.00	0	0

Sub Total

0.00

Indian

Bodies Corporate-Indian (Promoter & Group)	0	0.00	0	0
Government(Central / State)-Indian (Promoter & Group)	0	0.00	0	0
Directors & their Relatives-Indian (Promoter & Group)	0	0.00	0	0
Financial Institutions / Banks-Indian (Promoter & Group)	0	0.00	0	0
Individuals / Hindu Undivided Family-Indian (Promoter & Group)	3410746	1.21	3410746	5
Partnership Firms-Indian (Promoter & Group)	0	0.00	0	0
Persons Acting in Concert	0	0.00	0	0
Trusts	128241936	45.44	128241936	1
Others	0	0.00	0	0

Sub Total

131652682

46.65

131652682

Total ShareHolding for Promoter & Group

131652682

46.65

131652682

Publice Share Holding

Institution

Government(Central / State)	107037	0.04	107037	3
Clearing Members	0	0.00	0	0
Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
Financial Institutions / Banks	182788	0.06	182788	3
Foreign Bank	0	0.00	0	0
Foreign Bodies Corporate/OCBs/FBC	0	0.00	0	0
Foreign Collaborators	0	0.00	0	0
Foreign Institutional Investors	57413527	20.35	57413527	346
Foreign Venture Capital Investors	0	0.00	0	0
Foreign Institution Other	0	0.00	0	0
Insurance Companies	2820878	1.00	2820878	17
Mutual Funds / UTI	47404903	16.80	47404903	36
Individuals (Non-Resident / Foreign)	0	0.00	0	0
NSDL Intransit	0	0.00	0	0
Others	4014428	1.42	4014428	31
Trusts	0	0.00	0	0
Venture Capital Funds	0	0.00	0	0

Sub total

111943561

39.67

111943561

436

Non Institution

Bodies Corporate	5972370	2.12	5972370	1196
Clearing Members	320381	0.11	320381	6
Directors & their Relatives	35	0.00	35	1
Employees	0	0.00	0	0
Escrow Account	0	0.00	0	0
Foreign Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
NRIs/Foreign Individuals/Foreign Nationals	2332405	0.83	2328405	6448
Foreign Non Institution Other	0	0.00	0	0
Hindu Undivided Families	510942	0.18	510942	3358
Indian Public	0	0.00	0	0
Individuals holding nominal share capital in excess of Rs. 1 lakh	7595046	2.69	6995046	14
Individuals holding nominal share capital up to Rs. 1 lakh	21519793	7.63	21309959	184629
Market Maker	0	0.00	0	0
NSDL Transit	0	0.00	0	0
Shares in transit	0	0.00	0	0
Societies	0	0.00	0	0
Trust & Foundation	59886	0.02	59886	8
Others	293708	0.10	293708	3

Sub Total

38604566

13.68

37790732

195663

Total Public Shareholding

150548127

53.35

149734293

196099

Total of Promoter & Public ShareHolding

282200809

100.00

281386975

196105

Shares held by Custodians and against which Depository Receipts have been issued

ADR	0	0.00	0	0
GDR	0	0.00	0	0
Other Custodians	0	0.00	0	0

Total Shares held by Custodians and against which Depository Receipts have been issued

0.00

Grand Total

282200809

100.00

281386975

196105

Financials (₹ in cr)

Consolidated Standalone

Year End	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Net Sales	13,321.74	11,813.10	11,583.24	12,304.90	10,943.93
OPM (%)	13.30	7.94	8.68	13.83	12.23
OP	1,772.03	937.45	1,005.70	1,702.16	1,337.93
Other Income	113.72	839.99	288.90	166.67	50.22
PBIDT	2,092.28	1,134.37	1,158.05	2,226.06	2,179.14
INTEREST	207.07	515.97	349.04	298.10	353.11
PBDT	1,885.22	618.40	809.02	1,927.96	1,826.03
PBT	1,026.39	-864.46	-526.01	1,180.33	1,427.02
EO	-372.82	-900.96	-765.85	-260.91	44.55
PBT after EO	1,399.21	36.50	239.84	1,441.25	1,382.48
TAXES	352.07	1,867.35	329.40	447.60	412.39
PAT	1,047.10	-1,501.67	297.25	941.71	970.04
EPS	37.11	-53.22	10.53	33.37	34.38
Raw Material	22.53	26.73	27.50	26.65	27.95
Power and Fuel	0.78	0.79	0.75	1.47	1.30
Employee Cost	22.69	24.28	22.45	19.89	21.42
Other Manufacturing Expenses	0.67	1.06	0.60	0.60	0.41
Selling and Administration Expenses	14.82	14.41	15.13	12.54	13.28
Miscellaneous Expenses	5.91	6.42	5.57	5.66	5.84
Revenue (Growth %)	12.77	1.98	-5.86	12.44	2.85
PBIDT (Growth %)	84.44	-2.04	-47.98	2.15	15.26
PAT (Growth %)	-169.73	-605.20	-68.44	-2.92	25.01
PBIDT (Margin %)	15.71	9.60	10.00	18.09	19.91
PAT (Margin %)	7.86	-12.71	2.57	7.65	8.86

Balance Sheet (₹ in cr)

Particulars (Sources Of Funds)	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Share Capital	28.22	28.22	28.22	28.22	28.22	28.22
Reserves Total	24475.74	22942.40	17849.25	16710.37	14781.29	13198.05
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	24503.96	22970.62	17877.47	16738.59	14809.51	13226.27
Secured Loans	298.82	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	530.97	707.29	3221.22	3737.70	3703.99	3573.76
Total Debt	829.79	707.29	3221.22	3737.70	3703.99	3573.76
Other Liabilities	132.10	131.94	372.58	121.32	136.61	205.65
Total Liabilities	25465.85	23809.85	21471.27	20597.61	18650.11	17005.68
APPLICATION OF FUNDS :
Gross Block	3743.15	3392.75	3183.65	3026.28	2848.56	2595.06
Less : Accumulated Depreciation	1763.97	1636.50	1437.70	1273.95	1126.07	983.11
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	1979.18	1756.25	1745.95	1752.33	1722.49	1611.95
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	154.56	197.67	172.34	109.04	131.40	200.01
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	15194.91	12964.79	10334.01	8559.39	6989.95	4713.93
Current Assets, Loans & Advances
Inventories	1369.31	1142.69	1090.21	951.66	762.39	837.50
Sundry Debtors	2550.16	2484.47	2505.66	2678.32	2488.75	1835.24
Cash and Bank Balance	132.74	129.15	93.79	29.63	15.79	88.26
Loans and Advances	725.47	925.17	695.51	743.31	1642.20	1662.89
Total Current Assets	4777.68	4681.48	4385.18	4402.93	4909.12	4423.89
Less : Current Liabilities and Provisions
Current Liabilities	2383.39	3249.79	2952.14	2168.39	1834.31	1827.48
Provisions	125.79	354.74	162.52	148.49	133.11	118.45
Total Current Liabilities & Provisions	2509.18	3604.54	3114.66	2316.88	1967.41	1945.92
Net Current Assets	2268.50	1076.94	1270.52	2086.05	2941.71	2477.97
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	166.59	475.61	1160.25	1137.47	1118.72	1081.34
Deferred Tax Liability	224.85	309.77	213.50	214.20	265.43	276.60
Net Deferred Tax	-58.26	165.84	946.75	923.27	853.29	804.74
Other Assets	5926.97	7648.37	7001.70	7167.54	6011.27	7197.08
Total Assets	25465.86	23809.85	21471.26	20597.62	18650.11	17005.68
Contingent Liabilities	2949.43	2658.49	3443.30	3325.06	3730.17	4430.59

Cash Flow (₹ in cr)

Yearly Cash Flow	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Financing Activities	-80.79	-305.12	-978.50	-2,666.45	-95.41
Investing Activities	-1,235.19	-897.02	-431.52	3,197.17	-489.90
Net Cash Flow	-72.57	13.93	64.05	35.27	3.49
Operating Activities	1,243.42	1,216.07	1,474.06	-495.45	588.80

Peers

Balance Sheet Financial Ratios Profit & Loss

No Data Available!!!

Corporate Actions

Bonus Dividends Splits

Date	Corporate Action	Information
No Corporate Actions Announced

Board of Directors

Chairman & Chief Executive Officer

Glenn Saldanha

Chairman / Executive Director / M D / Promoter

Executive

Functional Directors

BES

B E Saldanha

Non Executive Director

Exec.

Independent Directors

SSR

Sona Saira Ramasastry

Independent Non Exe. Director

Ind.

Dipankar Bhattacharjee

Independent Non Exe. Director

Ind.

VRI

V R Iyer

Independent Non Exe. Director

Ind.

PKS

Pradeep Kumar Sinha

Independent Non Exe. Director

Ind.

Other Officials

Cheryl Pinto

ED / WTD / Promoter

Board

Anurag Mantri

ED / President / Global CFO

Board

Harish Kuber

Company Sec. & Compli. Officer

Board

Frequently Asked Questions

What is the NSE symbol and BSE code for Glenmark Pharmaceuticals Ltd? −

Glenmark Pharmaceuticals Ltd trades on NSE under GLENMARK and on BSE under code 532296. The ISIN is INE935A01035 and the face value is Rs 1.

What is the share price of Glenmark Pharmaceuticals Ltd today? +

As of 11 July 2026, Glenmark Pharmaceuticals Ltd trades at Rs 2,282.90, a change of 15.70 (0.69%) on the day. Prices are live and subject to change.

What is the market capitalisation of Glenmark Pharmaceuticals Ltd? +

As of 11 July 2026, Glenmark Pharmaceuticals Ltd has a market cap of about Rs 64405.28 crore. This figure is live and moves with the share price.

Is Glenmark Pharmaceuticals Ltd profitable? +

In March 2025, Glenmark Pharmaceuticals Ltd reported a profit after tax of Rs 1,047.10 crore. The wording switches to "a net loss of Rs X crore" when the figure is negative.

What is the PE ratio of Glenmark Pharmaceuticals Ltd? +

: As of 11 July 2026, the PE (TTM) for Glenmark Pharmaceuticals Ltd is 40.25 and the price-to-book ratio is 2.67. When the PE shows zero, state that PE TTM is currently not applicable and give the PB only.

Does Glenmark Pharmaceuticals Ltd pay a dividend? +

As of 11 July 2026, the dividend yield for Glenmark Pharmaceuticals Ltd is 0.11%. The wording switches to "does not currently pay a dividend" when the yield is zero.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd? +

As of the latest disclosed pattern, promoters hold 46.65% of Glenmark Pharmaceuticals Ltd. Public shareholding is 53.35%, including mutual funds at 16.80% and foreign institutional investors at 20.35%.

What were the latest annual financials of Glenmark Pharmaceuticals Ltd? +

In March 2025, Glenmark Pharmaceuticals Ltd reported net sales of Rs 13,321.74 crore, revenue growth of 12.77%, and earnings per share of Rs 37.11.

Invest with clarity

on Chola Securities Mobile & Web App.

Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.

Download the app now → The new app is listed as Chola Securities- Prime Access on App store & Google Play.
Also available on Web, Click to explore